ARTICLE | Clinical News
Lagova: Completed Phase III enrollment
July 20, 2015 7:00 AM UTC
Opko completed enrollment in a double-blind, placebo-controlled, international Phase III trial evaluating once-weekly hGH-CTP for 26 weeks in about 189 patients. The trial includes a 26-week open-labe...